Literature DB >> 2934513

Chronic 5-HT2 receptor blockade with ritanserin does not reduce blood pressure in the spontaneously hypertensive rat.

K Gradin, A Pettersson, T Hedner, B Persson.   

Abstract

Chronic oral treatment (8 weeks) with the selective 5-hydroxytryptamine2 (5-HT2)-receptor blocking agent, ritanserin, did not reduce blood pressure in the spontaneously hypertensive rat (SHR) during basal conditions or during stress (jet air). In pithed rats the pressor responses to 5-HT but not to phenylephrine or sympathetic stimulation of the sympathetic outflow were completely antagonized. These observations indirectly suggests that the 5-HT2-receptor blocking properties of the antihypertensive agent ketanserin cannot alone account for the antihypertensive effects in SHR that are observed during chronic treatment with this agent.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2934513     DOI： 10.1007/bf01245975

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  9 in total

1.  A pithed rat preparation suitable for assaying pressor substances.

Authors:  R E SHIPLEY; J H TILDEN
Journal:  Proc Soc Exp Biol Med       Date:  1947-04

2.  Involvement of alpha-adrenergic receptors at different levels of the central nervous system in the regulation of blood pressure and heart frequency.

Authors:  G G Trolin
Journal:  Acta Physiol Scand Suppl       Date:  1975

3.  Mechanism of the hypotensive effect of ketanserin.

Authors:  J R Fozard
Journal:  J Cardiovasc Pharmacol       Date:  1982 Sep-Oct       Impact factor: 3.105

4.  Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors.

Authors:  J E Leysen; F Awouters; L Kennis; P M Laduron; J Vandenberk; P A Janssen
Journal:  Life Sci       Date:  1981-03-02       Impact factor: 5.037

5.  Renal function and sympathetic activity during mental stress in normotensive and spontaneously hypertensive rats.

Authors:  S Lundin; P Thorén
Journal:  Acta Physiol Scand       Date:  1982-05

6.  Vascular effects of ketanserin (R 41 468), a novel antagonist of 5-HT2 serotonergic receptors.

Authors:  J M Van Nueten; P A Janssen; J Van Beek; R Xhonneux; T J Verbeuren; P M Vanhoutte
Journal:  J Pharmacol Exp Ther       Date:  1981-07       Impact factor: 4.030

7.  Antihypertensive effects of ketanserin in the spontaneously hypertensive rat: mode of action.

Authors:  K Gradin; A Pettersson; T Hedner; B Persson
Journal:  J Cardiovasc Pharmacol       Date:  1985       Impact factor: 3.105

8.  Ketanserin in essential hypertension: effects during rest and exercise.

Authors:  B Persson; T Hedner; G Berglund
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

9.  Antihypertensive effects of chronic 5-hydroxytryptamine (5-HT2) receptor blockade with ketanserin in the spontaneously hypertensive rat.

Authors:  A Pettersson; B Persson; M Henning; T Hedner
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-08       Impact factor: 3.000
  9 in total
  10 in total

Review 1.  Serotonin and blood pressure regulation.

Authors:  Stephanie W Watts; Shaun F Morrison; Robert Patrick Davis; Susan M Barman
Journal:  Pharmacol Rev       Date:  2012-03-08       Impact factor: 25.468

Review 2.  Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

Review 3.  Serotonin and vascular disease: a survey.

Authors:  J I Robertson
Journal:  Cardiovasc Drugs Ther       Date:  1990-01       Impact factor: 3.727

Review 4.  5-hydroxtryptamine receptors in systemic hypertension: an arterial focus.

Authors:  Stephanie W Watts; Robert Patrick Davis
Journal:  Cardiovasc Ther       Date:  2011-02       Impact factor: 3.023

5.  Antihypertensive effects of chronic 5-hydroxytryptamine (5-HT2) receptor blockade with irindalone in the spontaneously hypertensive rat.

Authors:  K Gradin; T Hedner; B Persson
Journal:  J Neural Transm Gen Sect       Date:  1991

Review 6.  Oh, the places you'll go! My many colored serotonin (apologies to Dr. Seuss).

Authors:  Stephanie W Watts
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-09-23       Impact factor: 4.733

7.  Cardiovascular effects of intrathecal administration of substance P in the rat: interactions with serotonergic mechanisms.

Authors:  K Gradin; B Persson
Journal:  J Neural Transm Gen Sect       Date:  1992

8.  Serotonin-induced platelet aggregation predicts the antihypertensive response to serotonin receptor antagonists.

Authors:  G Gleerup; B Persson; T Hedner; K Winther
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

9.  The effects of the 5 HT2 antagonist ritanserin on blood pressure and serotonin-induced platelet aggregation in patients with untreated essential hypertension.

Authors:  D J Stott; A R Saniabadi; J Hosie; G D Lowe; S G Ball
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

10.  Functional role of 5-HT2 receptors in the regulation of sleep and wakefulness in the rat.

Authors:  C Dugovic; A Wauquier; J E Leysen; R Marrannes; P A Janssen
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.